Waiting for Molecular and Biomarker Test Results

You have already been through a biopsy and had a pathology result. Now you are being asked to wait again, sometimes for weeks, before treatment is decided. This second wait is often harder than the first. You already know you have cancer, and it feels as though nothing is happening.

Something is happening. Molecular and biomarker testing looks past what the cells look like under a microscope. It looks at what is driving them. That means specific gene mutations, fusions, amplifications, protein expression levels, and features such as microsatellite instability or tumor mutational burden. These findings decide whether a targeted therapy or immunotherapy applies to you. Starting the wrong treatment first can close off options. In some situations it causes harm.

Tissue from your biopsy or surgery is cut into sections. The lab first checks whether enough tumor is present to test at all. DNA, and sometimes RNA, is then pulled out and prepared into a sequencing library. The sample is sequenced, often across hundreds of genes at once. Software pipelines then sort meaningful alterations from background noise. A molecular pathologist reviews the output and issues a report. That report says which findings are clinically actionable, meaning they can guide treatment.

Each step has a queue. Many hospitals do not run these tests in-house. They send specimens to a reference laboratory, which adds shipping and intake time at both ends. Immunohistochemistry (a stain that shows which proteins a cell is making) for a single marker may take days. Comprehensive genomic profiling on tissue commonly takes two to four weeks. A blood-based test is usually faster. This is a liquid biopsy, which detects tumor DNA circulating in plasma. It often comes back in around a week, and it is sometimes run in parallel to get an early answer.

Insufficient tissue is the most frequent problem. Needle biopsies are small by design. After the diagnostic staining, there may not be enough tumor left. If this happens you may be offered a repeat biopsy, a liquid biopsy, or both. This is a known limit of small samples, not a mistake.

Some specimens need decalcification, which removes calcium from bone. That takes time and can damage DNA. Some results come back equivocal, meaning unclear, and need a confirming test. Occasionally a run fails quality control and has to be repeated. None of these delays tell you anything about how serious your cancer is.

This depends on your cancer and your symptoms. It is a reasonable thing to ask about directly.

In some settings, guidance advises waiting for biomarker results before starting systemic therapy. Advanced non-small cell lung cancer is the clearest example. The reason is specific. Someone may turn out to have a targetable driver mutation. If they were given immunotherapy first, starting the targeted drug afterwards can cause serious toxicity. In other situations, treatment that will be given regardless can start while testing runs. And sometimes symptoms are pressing enough that starting is right even with results outstanding.

So ask this: does my treatment plan depend on these results, and if so, is there any risk in the delay? A specific answer usually exists.

Results arrive in categories. An actionable alteration means there is an approved drug, or a trial, matched to that finding. A variant of uncertain significance means a change was detected but its meaning is not yet known. It is not something to act on, and it is not a hidden warning. "No actionable alterations" is common, and it is not a bad result. It narrows the plan to standard therapy. It does not mean your cancer is untreatable.

Most alterations found in tumor testing are picked up by the tumor itself and are not inherited. If something is found that might be inherited, your team should raise genetic counseling separately. A blood sample is the only way to confirm it.

Finally, tumors change. A biomarker profile is a snapshot of one moment. If your cancer progresses later, retesting is often recommended. What is driving it then may not be what drove it at diagnosis.

• American Lung Association — Biomarker Testing FAQs (turnaround times, insufficient tissue)
• American Cancer Society — Waiting for Your Biopsy or Cytology Test Results
• NCI Dictionary — Biomarker testing